Company profile: Acelyrin
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies, identifying, acquiring, and accelerating development and commercialization of candidates including Izokibep (IL-17A inhibitor for psoriatic arthritis and hidradenitis suppurativa), Lonigutamab (subcutaneous anti-IGF-1R for thyroid eye disease), and SLRN-517 (fully human monoclonal targeting c-KIT for chronic urticaria and other mast cell-driven diseases).
Products and services
- SLRN-517: A fully human monoclonal antibody targeting c-KIT, engineered for chronic urticaria and potentially other mast cell-driven diseases
- Lonigutamab: A subcutaneously delivered anti-IGF-1R antibody, built to target the IGF-1 receptor and being evaluated for thyroid eye disease
- Izokibep: A small therapeutic protein inhibitor of interleukin-17A (IL-17A), engineered for diseases like psoriatic arthritis and hidradenitis suppurativa, targeting IL-17A
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Acelyrin
Euroimmun
HQ: Germany
Website
- Description: Provider of medical laboratory diagnostics, designing, manufacturing, and selling disease detection test systems, with software and automation for test execution and evaluation. Products are used to diagnose autoimmune and infectious diseases; offerings include EURORealTime APOE, EURORealTime RSV A/B, SwiftX-traction, Chemiluminescence Immunoassays (ChLIA), and training via EUROIMMUN Academy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Euroimmun company profile →
Dianthus Therapeutics
HQ: United States
Website
- Description: Provider of targeted therapeutics for serious autoimmune diseases, including DNTH103, a long-acting monoclonal antibody that selectively inhibits active C1s in the classical complement pathway. DNTH103 is in Phase 2 for generalized myasthenia gravis, with plans for multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy, using YTE half-life extension for less frequent dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dianthus Therapeutics company profile →
Cellenkos
HQ: United States
Website
- Description: Provider of clinical-stage allogeneic cord blood regulatory T cell therapeutics for autoimmune and inflammatory disorders, enabled by the proprietary CRANE platform for cell enrichment and differentiation and in-house cGMP manufacturing. Pipeline includes CK0801 for bone marrow failure syndromes, CK0802 for COVID-19 ARDS, and CK0804 for myelofibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellenkos company profile →
vTv Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule therapeutics addressing unmet medical needs, including: TTP399, a liver-selective glucokinase activator adjunct to insulin for type 1 diabetes to reduce hypoglycemia; HPP737, a PDE4 inhibitor for psoriasis with potential in COPD and atopic dermatitis; TTP273, an oral GLP-1 receptor agonist for type 2 diabetes; and a Nrf2/Bach1 program to reduce oxidative stress and inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full vTv Therapeutics company profile →
Santa Ana Bio
HQ: United States
Website
- Description: Provider of precision immunology drug development for autoimmune and inflammatory diseases, using single-cell genomics and advanced analytics to develop drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Santa Ana Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Acelyrin
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Acelyrin
2.2 - Growth funds investing in similar companies to Acelyrin
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Acelyrin
4.2 - Public trading comparable groups for Acelyrin
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →